Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Watch Now

upload.jpg

James Graham, CEO of Recce Pharmaceuticals (ASX:RCE) shares that the company is advancing its antibiotic treatments for diabetic foot infections. Recce (ASX:RCE) has received approval for a phase three clinical trial in Indonesia, targeting a population of 280 million, 11% of which have diabetes. James sees this as a gateway to the ASEAN markets, reaching 700 million people, presenting significant commercial opportunities.

Ausbiz Interview - Recce Pharmaceuticals (RCE)